Solid Dispersion Bioavailability via Melt Extrusion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Solid oral dosage forms of pharmaceutical agents often exhibit lower bioavailability due to poor aqueous solubility, which limits their effectiveness compared to liquid solutions, and existing methods for improving bioavailability, such as solid dispersions, may result in less than optimal homogeneity and dissolution rates.
Innovation Solution
A solid dispersion product is created through a melt-extrusion process using an effective amount of active ingredients and hydroxypropyl methylcellulose, where the ΔHtr value is optimized between 0.35 and 0.15 J/g at a temperature range of 230 °C to 260 °C, ensuring a highly homogeneous matrix for enhanced bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If solid oral dosage forms are used, then patient compliance and taste-masking are improved, but bioavailability decreases due to poor aqueous solubility
Solution Approach 1:
The patent changes the physical state of the active ingredient from crystalline to amorphous form within a solid dispersion matrix. This parameter change in molecular arrangement and energy state increases aqueous solubility and bioavailability while maintaining the solid dosage form for patient compliance
Solution Approach 2:
The patent creates a composite solid dispersion system combining the active ingredient with a hydrophilic carrier material. This composite structure leverages the solubility properties of the carrier to enhance the bioavailability of the poorly water-soluble active ingredient while maintaining solid form benefits
2Reliability
If solid dispersions are prepared by conventional methods, then bioavailability is improved, but homogeneity of the product deteriorates
Solution Approach 1:
The patent replaces conventional mechanical mixing and grinding methods with a melt extrusion process. This substitution uses thermal energy and shear forces within the extruder to achieve molecular-level dispersion and homogeneous mixing, eliminating the fibrous aggregates that occur with mechanical methods
Solution Approach 2:
The patent utilizes phase transitions of the hydrophilic carrier material through melting and cooling cycles during extrusion. The carrier melts to form a homogeneous matrix that incorporates the active ingredient, then cools to form a uniform solid dispersion, avoiding the heterogeneity of mechanical mixing
3Ease of manufacture
If crystalline or microcrystalline solid phase is used, then manufacturing is simplified, but dissolution rate decreases
Solution Approach 1:
The patent changes the physical state of the active ingredient from crystalline to amorphous form within a solid dispersion matrix. This parameter change in molecular arrangement and energy state increases aqueous solubility and bioavailability while maintaining the solid dosage form for patient compliance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The optimized solid dispersion product demonstrates improved bioavailability by achieving a more homogeneous matrix, leading to faster dissolution and increased therapeutic efficacy of poorly water-soluble active ingredients.
Implementation Method 1
converting a melt of polymeric binder that contains active ingredients and that is free from solvents into the required drug form by injection molding or extrusion and subsequent shaping
Implementation Method 2
the endotherm (J/g) accompanying a transition at an endothermic peak temperature in the range of from 230 °C to 260 °C
Implementation Method 3
a melting endotherm curve is first prepared by the following method using a differential scanning calorimeter
Data Source
AI summary
A solid dispersion product comprising an effective amount of one or more active ingredients and an effective amount of one or more hydroxypropyl methylcellulose(s), which satisfies the Formula 0.35 > ?Htr (1) (wherein AHtr represents the endotherm (J/g) accompanying a transition at about 240° C). The solid dispersion product is used for the manufacture of a dosage form having improved bioavailability of said one or more active ingredients by oral administration to a patient in need thereof.